Physiological relevance or ease of use? Enjoy both with hTERT-immortalized Primary CellsOctober 18, 2018, at 12:00 PM ET
Two challenges that scientists experience when developing a cell-based assay include obtaining cells with biological relevance and then producing or procuring enough cells to run the assay without introducing cell variability. hTERT-immortalized primary cells address both issues. These cells are genetically modified such that the cells exhibit the growth characteristics of a continuous cell line but maintain the physiology of a primary cell. In this webinar, ATCC scientists will discuss our broad portfolio of hTERT-immortalized primary cells and provide some application data to illustrate how these cell models can easily be incorporated into your workflow.
- hTERT-immortalized primary cells solve the problem of limited biological relevancy in cell-based assays
- hTERT-immortalized primary cells exhibit the growth characteristics of a continuous cell line but maintain the physiology of a primary cell
- ATCC has created kidney cell models using a well-characterized hTERT-immortalized RPTEC that stably overexpress the OAT1, OCT2, or OAT3 gene
- Our data show that these modified cell lines are effective tools that provide tissue-relevant results, improved consistency over time, and predictability for clinical trials
Kevin Grady, BS
Manager, Product Management, ATCC
Kevin Grady is the Manager of Product Management at ATCC. He has been with ATCC for 8 years; prior to ATCC, he held positions at Lonza as Global Product Manager and Director of Scientific Support. Kevin has a long history in the life science industry additionally serving as Director of Scientific Support at Amaxa and Manager of Technical Support at Life Technologies. Mr. Grady has always found great satisfaction in helping researchers learn how to use available products and tools to be more productive and successful in reaching their research goals.
Chaozhong Zou, PhD
Senior Scientist, ATCC Cell Systems
Dr. Chaozhong Zou is a Senior Scientist and the Group Leader of the Immortalized Cells group at ATCC Cell Systems. Dr. Zou has extensive experience in cell-related product development such as immortalized cell lines, stable reporter cell lines, and cell-based assays development. Dr. Zou was a research scientist at NorthShore University HealthSystem, University of Chicago Medical School and conducted postdoctoral research at Northwestern University and Tufts University.